Co-Authors
This is a "connection" page, showing publications co-authored by VARSHA V GANDHI and CHRISTINE STELLRECHT.
Connection Strength
4.054
-
Chlorinated adenosine analogue induces AMPK and autophagy in chronic lymphocytic leukaemia cells during therapy. Br J Haematol. 2017 10; 179(2):266-271.
Score: 0.610
-
A unique RNA-directed nucleoside analog is cytotoxic to breast cancer cells and depletes cyclin E levels. Breast Cancer Res Treat. 2010 Jun; 121(2):355-64.
Score: 0.351
-
Myeloma antioxidant status: the good, the bad and the reactive. Leuk Lymphoma. 2009 May; 50(5):691-3.
Score: 0.345
-
MET receptor tyrosine kinase as a therapeutic anticancer target. Cancer Lett. 2009 Jul 18; 280(1):1-14.
Score: 0.336
-
Multiple myeloma cell killing by depletion of the MET receptor tyrosine kinase. Cancer Res. 2007 Oct 15; 67(20):9913-20.
Score: 0.310
-
RNA-directed actions of 8-chloro-adenosine in multiple myeloma cells. Cancer Res. 2003 Nov 15; 63(22):7968-74.
Score: 0.236
-
Concurrent isolation of ribosomal, messenger, and low molecular weight RNA. Biotechniques. 2002 Nov; 33(5):1122-4.
Score: 0.220
-
The role of p53 and p21 on 8-chloro-adenosine-induced cellular response. Nucleosides Nucleotides Nucleic Acids. 2022; 41(12):1359-1374.
Score: 0.210
-
Ataxia-telangiectasia mutated interacts with Parkin and induces mitophagy independent of kinase activity. Evidence from mantle cell lymphoma. Haematologica. 2021 02 01; 106(2):495-512.
Score: 0.195
-
PIM kinase inhibitor, AZD1208, inhibits protein translation and induces autophagy in primary chronic lymphocytic leukemia cells. Oncotarget. 2019 Apr 19; 10(29):2793-2809.
Score: 0.172
-
The Stromal Microenvironment Modulates Mitochondrial Oxidative Phosphorylation in Chronic Lymphocytic Leukemia Cells. Neoplasia. 2017 Oct; 19(10):762-771.
Score: 0.154
-
B-cell Receptor Signaling Regulates Metabolism in Chronic Lymphocytic Leukemia. Mol Cancer Res. 2017 12; 15(12):1692-1703.
Score: 0.153
-
Erratum to: Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines. J Hematol Oncol. 2016 10 13; 9(1):110.
Score: 0.145
-
Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells. Neoplasia. 2015 Mar; 17(3):289-300.
Score: 0.129
-
Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines. J Hematol Oncol. 2013 Dec 10; 6:92.
Score: 0.119
-
Targeting MET transcription as a therapeutic strategy in multiple myeloma. Cancer Chemother Pharmacol. 2009 Mar; 63(4):587-97.
Score: 0.081
-
RNA-directed agent, cordycepin, induces cell death in multiple myeloma cells. Br J Haematol. 2008 Mar; 140(6):682-391.
Score: 0.079
-
Cell death of bioenergetically compromised and transcriptionally challenged CLL lymphocytes by chlorinated ATP. Blood. 2005 Jun 01; 105(11):4455-62.
Score: 0.064
-
Mechanisms for T-cell selective cytotoxicity of arabinosylguanine. Blood. 2003 Sep 01; 102(5):1842-8.
Score: 0.057
-
Enhanced Vulnerability of LKB1-Deficient NSCLC to Disruption of ATP Pools and Redox Homeostasis by 8-Cl-Ado. Mol Cancer Res. 2022 02; 20(2):280-292.
Score: 0.051
-
Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma. Ann Hematol. 2017 Jun; 96(6):977-985.
Score: 0.037